



500 Linden Oaks
Rochester, New York 14625

FOR IMMEDIATE RELEASE

CONTACT: Investor Relations Contact:
BPC Financial Marketing
John Baldissera
(800)368.1217

Company Contact:
Molly Henderson
Chief Business and Financial Officer
500 Linden Oaks
Rochester, New York 14625
(585)249.6231

**VIRTUALSCOPICS INTRODUCES INNOVATIVE NEW GUARANTEE TO CAPTURE
ADDITIONAL MARKET SHARE**

First of its Kind Offering in the Industry

ROCHESTER, N.Y. – June 2, 2008 – VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of quantitative imaging for clinical trials, announced, effective today, it will begin offering a service guarantee for new oncology clinical trial projects. The guarantee called the “VirtualScopics Promise” will provide its customers with quality on-time data or the analysis fee will not be charged. The company is able to offer this commitment due to the inherent quality and productivity benefits allowed by its algorithm-based approach to imaging in clinical trials.

“We are very confident in our ability to deliver accurate and timely information to our customers,” stated Jeff Markin, Chief Executive Officer of VirtualScopics, Inc. He added, “The robustness of our proprietary technology, coupled with operational processes designed around both the technology and our customers’ needs, enables us to offer what we believe is the first guarantee of its kind within the industry. Our goal continues to be to leverage our technology to get timely and precise information to our clients enabling them to get the right drugs to market sooner. By launching this guarantee, we are demonstrating our confidence in our ability to meet this goal.” He further added, “We expect that by offering the VirtualScopics Promise we will further differentiate ourselves within the industry.”

About VirtualScopics, Inc.

VirtualScopics, Inc. is a leading provider of quantitative imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics’ industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit www.virtualscopics.com.

####

Forward-Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission.